Format

Send to

Choose Destination
Neurology. 2017 Jun 13;88(24):2302-2309. doi: 10.1212/WNL.0000000000004029. Epub 2017 May 12.

Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.

Author information

1
From the Laboratory for Molecular Neurobiomarker Research (K.P., M.D.S., B.G.), Laboratory for Cognitive Neurology (R.V.) and Laboratory of Neurobiology (Center for Brain & Disease Research, VIB, Leuven) (P.V.D.), Department of Neurosciences, KU Leuven (University of Leuven); Laboratory Medicine (K.P., M.D.S.) and Department of Neurology (O.S., K.G.C., G.C., A.D., N.L., P.T., D.V.R., R.V., P.V.D.), University Hospitals Leuven, Belgium; Hans Berger Department of Neurology (B.S., T.P., T.M.R., N.F., B.H., M.R., A.R., A.G., O.W.W., J.G.) and Institute for Biochemistry (P.M., S.W., H.R.), Jena University Hospital, Germany; INSERM, U942 (S.G., C.P.), Groupe Hospitalier Lariboisière Fernand-Widal Saint-Louis, CMRR Paris Nord AP-HP, Université Paris Diderot, France. koen.poesen@uzleuven.be.
2
From the Laboratory for Molecular Neurobiomarker Research (K.P., M.D.S., B.G.), Laboratory for Cognitive Neurology (R.V.) and Laboratory of Neurobiology (Center for Brain & Disease Research, VIB, Leuven) (P.V.D.), Department of Neurosciences, KU Leuven (University of Leuven); Laboratory Medicine (K.P., M.D.S.) and Department of Neurology (O.S., K.G.C., G.C., A.D., N.L., P.T., D.V.R., R.V., P.V.D.), University Hospitals Leuven, Belgium; Hans Berger Department of Neurology (B.S., T.P., T.M.R., N.F., B.H., M.R., A.R., A.G., O.W.W., J.G.) and Institute for Biochemistry (P.M., S.W., H.R.), Jena University Hospital, Germany; INSERM, U942 (S.G., C.P.), Groupe Hospitalier Lariboisière Fernand-Widal Saint-Louis, CMRR Paris Nord AP-HP, Université Paris Diderot, France.

Abstract

OBJECTIVE:

To determine the diagnostic performance and prognostic value of phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) in CSF as possible biomarkers for amyotrophic lateral sclerosis (ALS) at the diagnostic phase.

METHODS:

We measured CSF pNfH and NfL concentrations in 220 patients with ALS, 316 neurologic disease controls (DC), and 50 genuine disease mimics (DM) to determine and assess the accuracy of the diagnostic cutoff value for pNfH and NfL and to correlate with other clinical parameters.

RESULTS:

pNfH was most specific for motor neuron disease (specificity 88.2% [confidence interval (CI) 83.0%-92.3%]). pNfH had the best performance to differentially diagnose patients with ALS from DM with a sensitivity of 90.7% (CI 84.9%-94.8%), a specificity of 88.0% (CI 75.7%-95.5%) and a likelihood ratio of 7.6 (CI 3.6-16.0) at a cutoff of 768 pg/mL. CSF pNfH and NfL levels were significantly lower in slow disease progressors, however, with a poor prognostic performance with respect to the disease progression rate. CSF pNfH and NfL levels increased significantly as function of the number of regions with both upper and lower motor involvement.

CONCLUSIONS:

In particular, CSF pNfH concentrations show an added value as diagnostic biomarkers for ALS, whereas the prognostic value of pNfH and NfL warrants further investigation. Both pNfH and NfL correlated with the extent of motor neuron degeneration.

CLASSIFICATION OF EVIDENCE:

This study provides Class II evidence that elevated concentrations of CSF pNfH and NfL can accurately identify patients with ALS.

PMID:
28500227
DOI:
10.1212/WNL.0000000000004029
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center